Wcn26-8280 Immune Checkpoint Inhibitor-Associated Minimal Change Disease - A Case of Successful Rechallenge

Immune checkpoint inhibitors (ICI) are a broad class of immunotherapy drugs used across a wide range of malignancies, but these treatments can also cause autoimmune complications. Minimal change disease (MCD) is rare side effect of ICI therapy and re-challenge of ICI therapy after treatment of MCD has been infrequently reported. We present the first case of successful ICI-rechallenge using low-dose steroid bridging resulting in sustained remission of proteinuria and continued oncologic response.